BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29259179)

  • 1. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
    Stieglitz E; Mazor T; Olshen AB; Geng H; Gelston LC; Akutagawa J; Lipka DB; Plass C; Flotho C; Chehab FF; Braun BS; Costello JF; Loh ML
    Nat Commun; 2017 Dec; 8(1):2127. PubMed ID: 29259179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.
    Olk-Batz C; Poetsch AR; Nöllke P; Claus R; Zucknick M; Sandrock I; Witte T; Strahm B; Hasle H; Zecca M; Stary J; Bergstraesser E; De Moerloose B; Trebo M; van den Heuvel-Eibrink MM; Wojcik D; Locatelli F; Plass C; Niemeyer CM; Flotho C;
    Blood; 2011 May; 117(18):4871-80. PubMed ID: 21406719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
    Schönung M; Meyer J; Nöllke P; Olshen AB; Hartmann M; Murakami N; Wakamatsu M; Okuno Y; Plass C; Loh ML; Niemeyer CM; Muramatsu H; Flotho C; Stieglitz E; Lipka DB
    Clin Cancer Res; 2021 Jan; 27(1):158-168. PubMed ID: 33139265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JMML genomics and decisions.
    Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic characteristics and survival analysis of 27 cases of juvenile myelomonocytic leukemia].
    Li JJ; Hu T; Li JH; Zhang ZX; Feng SQ; Shi XD; Zhang L; Cao J; Song ZL; Hu MZ; Zhong DX; Yue M; Fan W; Tang RH; Zou BH; Liu R
    Zhonghua Er Ke Za Zhi; 2023 Jan; 61(1):56-60. PubMed ID: 36594122
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.
    Sakaguchi H; Muramatsu H; Okuno Y; Makishima H; Xu Y; Furukawa-Hibi Y; Wang X; Narita A; Yoshida K; Shiraishi Y; Doisaki S; Yoshida N; Hama A; Takahashi Y; Yamada K; Miyano S; Ogawa S; Maciejewski JP; Kojima S
    PLoS One; 2015; 10(12):e0145394. PubMed ID: 26720758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
    [No Abstract]   [Full Text] [Related]  

  • 15. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
    Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
    Flotho C
    Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia.
    Kitazawa H; Okuno Y; Muramatsu H; Aoki K; Murakami N; Wakamatsu M; Suzuki K; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Kawashima N; Nishikawa E; Narita A; Nishio N; Hama A; Loh ML; Stieglitz E; Kojima S; Takahashi Y
    Blood Adv; 2021 Dec; 5(24):5507-5518. PubMed ID: 34580726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.